Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556228 · ClinicalTrials.gov registry record · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by VM Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 242
- Enrollment target
- 15
- Study locations
NCT03556228 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by VM Oncology. The registered enrollment target is 242 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower). The trial reports 15 study locations across 12 states.
The verdict
NCT03556228, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by VM Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 242 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Conditions Studied
Interventions
- DRUG VMD-928 100 mg Tablet
- DRUG VMD-928 Tablet and Pembrolizumab (200 mg)
Study Locations (15)
New Jersey
- Englewood Hospital and Medical Center (site 202) - Englewood
- Summit Medical Group (site 205) - Florham Park
- Atlantic Health System, Morristown Medical Center (site 124) - Morristown
Florida
- Holy Cross Hospital (site 213) - Fort Lauderdale
- Memorial Cancer Institute at Memorial Healthcare Systems (site 132) - Pembroke Pines
California
- Providence Medical Foundation (site 209) - Santa Rosa
Connecticut
- Hartford Hospital (site 210) - Hartford
District of Columbia
- The George Washington University Cancer Center (site 212) - Washington D.C.
New Mexico
- Presbyterian Kaseman Hospital (site 208) - Albuquerque
New York
- Weill Cornell Medicine, Cornell University (site 126) - New York
Ohio
- Taylor Cancer Research Center (site 204) - Maumee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2018-06-08 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03556228
The ClinicalTrials.gov registry entry for NCT03556228 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower). The listed sponsor is VM Oncology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which VMD-928 100 mg Tablet is the first listed.
NCT03556228 reports 15 study locations spanning 12 distinct geographic areas - top geographies include New Jersey, Florida, California.
Frequently Asked Questions
What is clinical trial NCT03556228 about?
NCT03556228 is a clinical study titled "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma". This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curati...
What is the current status of trial NCT03556228?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 242 participants. The study started on 2018-06-08. Estimated completion is 2028-06.
What conditions does trial NCT03556228 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Pancreatic Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT03556228?
The interventions under investigation include: VMD-928 100 mg Tablet (DRUG), VMD-928 Tablet and Pembrolizumab (200 mg) (DRUG).
Who is sponsoring clinical trial NCT03556228?
This trial is sponsored by VM Oncology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03556228 being conducted?
This trial has 15 study locations across California, Connecticut, District of Columbia, Florida, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.